- Home
- CNO vs MRUS Comparison
CNO vs MRUS Comparison
Compare CNO & MRUS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CNO
- MRUS
- Stock Information
- Founded
- CNO 1979
- MRUS 2003
- Country
- CNO United States
- MRUS Netherlands
- Employees
- CNO N/A
- MRUS N/A
- Industry
- CNO Accident &Health Insurance
- MRUS Biotechnology: Pharmaceutical Preparations
- Sector
- CNO Finance
- MRUS Health Care
- Exchange
- CNO Nasdaq
- MRUS Nasdaq
- Market Cap
- CNO 3.6B
- MRUS 4.1B
- IPO Year
- CNO 1987
- MRUS 2016
- Fundamental
- Price
- CNO $37.80
- MRUS $66.82
- Analyst Decision
- CNO Hold
- MRUS Strong Buy
- Analyst Count
- CNO 6
- MRUS 13
- Target Price
- CNO $41.00
- MRUS $88.54
- AVG Volume (30 Days)
- CNO 717.5K
- MRUS 645.9K
- Earning Date
- CNO 07-28-2025
- MRUS 08-04-2025
- Dividend Yield
- CNO 1.70%
- MRUS N/A
- EPS Growth
- CNO N/A
- MRUS N/A
- EPS
- CNO 2.88
- MRUS N/A
- Revenue
- CNO $4,297,100,000.00
- MRUS $54,732,000.00
- Revenue This Year
- CNO N/A
- MRUS $68.08
- Revenue Next Year
- CNO $3.06
- MRUS $0.09
- P/E Ratio
- CNO $13.07
- MRUS N/A
- Revenue Growth
- CNO N/A
- MRUS 42.77
- 52 Week Low
- CNO $30.32
- MRUS $33.19
- 52 Week High
- CNO $43.20
- MRUS $67.07
- Technical
- Relative Strength Index (RSI)
- CNO 52.63
- MRUS 77.27
- Support Level
- CNO $37.17
- MRUS $61.51
- Resistance Level
- CNO $37.99
- MRUS $64.00
- Average True Range (ATR)
- CNO 0.73
- MRUS 2.32
- MACD
- CNO 0.08
- MRUS 1.02
- Stochastic Oscillator
- CNO 89.01
- MRUS 97.35
About CNO CNO Financial Group Inc.
CNO Financial Group Inc is a holding company for a group of insurance companies that offers middle-income American consumers insurance and securities products through exclusive agents, independent producers, and direct marketing. Consumers are served through the phone, online, mail, face-to-face with agents, or sales channels. The company's operating segments include annuity, health, and life insurance product lines as well as the investment and fee revenue segments. Maximum revenue is generated from the health product line segment. Annuity premiums account for the majority of the total premiums collected. Annuity products include fixed index annuities, traditional fixed-rate annuities, and single-premium immediate annuity products.
About MRUS Merus N.V.
Merus NV is a clinical-stage immuno-oncology company. It develops bispecific antibody therapeutics. The company is developing full-length human multispecific antibody therapeutics, referred to as Biclonics. Merus has only one reportable segment comprising the discovery and development of bispecific therapeutics. Some of its products in the pipeline include MCLA-128; MCLA-117; MCLA-158 and others.